Q4 EPS Estimate for Elanco Animal Health Reduced by Analyst

Elanco Animal Health Incorporated (NYSE:ELAN) – Research analysts at Leerink Partnrs cut their Q4 2025 earnings estimates for shares of Elanco Animal Health in a note issued to investors on Wednesday, November 5th. Leerink Partnrs analyst D. Clark now forecasts that the company will post earnings of $0.11 per share for the quarter, down from their prior estimate of $0.14. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health’s FY2026 earnings at $0.98 EPS and FY2027 earnings at $1.15 EPS.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a return on equity of 7.51% and a net margin of 0.78%.The company’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS.

A number of other analysts have also recently issued reports on ELAN. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. Piper Sandler upped their target price on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, August 11th. Leerink Partners upgraded Elanco Animal Health from a “market perform” rating to an “outperform” rating and set a $18.00 target price for the company in a report on Thursday, July 17th. Stifel Nicolaus boosted their price target on Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Finally, JPMorgan Chase & Co. raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $18.00 to $24.00 in a research report on Tuesday, October 7th. Two investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.29.

Elanco Animal Health Trading Down 1.5%

Shares of NYSE ELAN traded down $0.33 during midday trading on Friday, reaching $21.19. 494,185 shares of the stock were exchanged, compared to its average volume of 5,904,285. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $22.98. The company has a market capitalization of $10.53 billion, a price-to-earnings ratio of 351.56, a P/E/G ratio of 3.30 and a beta of 1.71. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. The business has a 50-day simple moving average of $20.11 and a two-hundred day simple moving average of $16.07.

Institutional Investors Weigh In On Elanco Animal Health

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Allworth Financial LP grew its stake in shares of Elanco Animal Health by 791.7% in the first quarter. Allworth Financial LP now owns 2,354 shares of the company’s stock valued at $25,000 after buying an additional 2,090 shares in the last quarter. SJS Investment Consulting Inc. lifted its stake in Elanco Animal Health by 2,563.5% in the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after acquiring an additional 1,333 shares during the last quarter. Whittier Trust Co. of Nevada Inc. grew its position in shares of Elanco Animal Health by 80.3% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after acquiring an additional 900 shares during the period. Farther Finance Advisors LLC increased its stake in shares of Elanco Animal Health by 79.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after purchasing an additional 951 shares during the last quarter. Finally, First Horizon Advisors Inc. lifted its stake in Elanco Animal Health by 184.3% in the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock valued at $53,000 after purchasing an additional 2,414 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.